CUE
Cue BiopharmaNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$17.29M
P/E Ratio
—
EPS
$-0.28
Beta
1.58
52W High
$1.03
52W Low
$0.17
50-Day MA
$0.29
200-Day MA
$0.57
Dividend Yield
—
Profit Margin
-96.90%
Forward P/E
—
PEG Ratio
—
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biological drugs for the selective modulation of the human immune system to treat a variety of cancers, chronic infectious diseases, and autoimmune disorders. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $27.47M |
| Gross Profit (TTM) | $-7.38M |
| EBITDA | $-25.56M |
| Operating Margin | 8.92% |
| Return on Equity | -121.10% |
| Return on Assets | -44.60% |
| Revenue/Share (TTM) | $0.29 |
| Book Value | $0.27 |
| Price-to-Book | 0.66 |
| Price-to-Sales (TTM) | 0.63 |
| EV/Revenue | 0.0161 |
| EV/EBITDA | -1.76 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1292.00% |
| Shares Outstanding | $97.66M |
| Float | $97.07M |
| % Insiders | 0.56% |
| % Institutions | 22.31% |
Analyst Ratings
Consensus ($4.00 target)
1
BuyData last updated: 4/7/2026